Please be aware that this event has been cancelled.
The Commercial Excellence Summit – Where Strategy Meets Impact
The Commercial Excellence in Rare Disease Summit marks a pivotal moment in orphan drug development, as breakthroughs from major pharma players like AstraZeneca and Vertex, alongside the FDA’s Rare Disease Innovation Hub, drive innovation.
This one-of-a-kind summit is essential for stakeholders in the commercialization of rare disease therapies, offering unique opportunities to shape market access, product planning, pricing, reimbursement, and patient services.
Learn how to enhance patient access, refine forecasting for rare patient populations, and create strong value demonstration frameworks. Join us in Boston to address the growing challenges in rare disease commercialization, optimize your strategy and first and foremost help the patient.
Top 5 Benefits of Attending
Learn how industry leaders from Takeda and Alexion are aligning new product planning, HEOR, and patient access to design commercially viable launch strategies from the earliest stages.
Gain actionable insights into how Ventus Therapeutics is strategically prioritizing resources across multiple assets to maximize portfolio value, while Sobi shares how tailored launch strategies can be crafted for rare disease treatments in uncharted markets.
Gain practical frameworks to build pricing analogues in uncharted therapeutic areas, featuring real-world strategies from experts at Chiesi and Day One Bio.
Discover how companies like Jazz Pharmaceuticals and BioMarin are leveraging epidemiology, RWE, and diagnostic data to shape market potential and access strategy for rare and ultra- rare populations.
Learn how Amicus and BridgeBio are empowering patients and advocacy groups to co-create value stories, drive education, and enhance commercial impact in complex treatment landscapes.
Who Will You Meet?
This summit brings together the entire commercial journey, from early-stage product planning and evidence generation through to launch execution, market access, pricing, and long-term success -uniting the cross-functional teams driving rare disease therapies to market.
